Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:35:22 EDT Sun 25 Oct 2026
Enter Symbol
or Name
USA
CA



News last 24 hour(s) - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-10-24 23:57U:GXRFFNews ReleaseProspera Energy Announces Service Rig Update as Luseland Workovers Come Online at 3.3x Prior Rates
2026-10-24 20:00U:ELEKNews ReleaseFrom Record-High Market Excitement to American Lithium Ambition: Elektros Looks North
2026-10-24 19:30U:ELEKNews ReleaseWall Street Fever, an Early Christmas in October: Penny Stock Lovers, This Is Your Time To Shine
2026-10-24 19:30U:CLYMNews ReleaseClimb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
2026-10-24 16:06U:GGIINews ReleaseSiren's Tale Vodka to Exhibit at SoCal Cocktail and Spirits Fest
2026-10-24 15:19U:TECKNews ReleaseTeck Provides Update on Highland Valley Copper Operations
2026-10-24 13:00U:AXONNews ReleaseAxon Announces Body 5: Next-Generation Camera Built for the AI Era
2026-10-24 11:18U:PFENews ReleasePfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
2026-10-24 10:35U:AZNNews ReleaseIMFINZI(TM) (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
2026-10-24 10:30U:AZNNews ReleasePerioperative IMFINZI(TM) (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
2026-10-24 10:30U:AMGNNews ReleaseIMDELLTRA(TM) IN COMBINATION WITH IMFINZI(TM) REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
2026-10-24 08:45U:PBLSNews ReleaseParabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
2026-10-24 08:00U:SMTCNews ReleaseSemtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
2026-10-24 08:00U:BAYZFNews ReleaseESMO 2026: NUBEQA(TM) (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
2026-10-24 08:00U:BAYRYNews ReleaseESMO 2026: NUBEQA(TM) (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
2026-10-24 07:01U:INCYNews ReleaseGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
2026-10-24 07:01U:GMABNews ReleaseGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
2026-10-24 07:00U:NBTXNews ReleaseNANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
2026-10-24 07:00U:INCYNews ReleaseIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
2026-10-24 05:30U:JNJNews ReleaseJohnson & Johnson announces ERLEADA(TM) (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
2026-10-24 04:15U:ONCNews ReleaseBeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
2026-10-24 04:15U:CMPXNews ReleaseCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
2026-10-24 04:15U:CELCNews ReleaseCelcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
2026-10-24 02:30U:ZYMENews ReleaseZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
2026-10-24 02:30U:LLYNews ReleaseLilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRalpha-targeting ADC at ESMO 2026
2026-10-24 02:30U:IMTXNews ReleaseImmatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting